



Singh, J., McElroy, M., and Quinn, T. (2015) Feasibility of recommended cognitive screening tools for older adults in carehomes. *Journal of the American Geriatrics Society*, 63(11), pp. 2432-2434.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

This is the peer reviewed version of the following article: Singh, J., McElroy, M., and Quinn, T. (2015) Feasibility of recommended cognitive screening tools for older adults in carehomes. *Journal of the American Geriatrics Society*, 63(11), pp. 2432-2434, which has been published in final form at <http://dx.doi.org/10.1111/jgs.13808>. This article may be used for non-commercial purposes in accordance with [Wiley Terms and Conditions for Self-Archiving](#).

<http://eprints.gla.ac.uk/113924/>

Deposited on: 25 January 2016

1           **Feasibility of recommended cognitive screening tools for older adults in carehomes**

2                           Jade Singh MBChB<sup>1</sup>, Morven McElroy MBChB<sup>2</sup>, Terence J Quinn MD<sup>3</sup>

3    1.        School of Medicine, University of Glasgow, Glasgow, UK

4    2.        Department of Geriatric Medicine, Glasgow Royal Infirmary, Glasgow, UK

5    3.        Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK

6    **Abbreviated title:** Cognitive screening in carehomes

7    **Funding source:** This work was supported by a British Geriatric Society Medical Student Elective  
8    grant. Dr Quinn is supported by a Chief Scientist Office/Stroke Association Senior Lecturer  
9    Fellowship.

10   **Address correspondence to:**

11    Dr Terry Quinn

12    Institute of Cardiovascular and Medical Sciences, University of Glasgow

13    Room 2.44, New Lister Building

14    Glasgow Royal Infirmary, Alexandra Parade, Glasgow UK, G31 2ER

15

16    **Email:** terry.quinn@glasgow.ac.uk

17    **Tel:** +441412018510

18    **Key words:** Dementia; Diagnosis; Feasibility; Nursing Homes; Screening; Skilled Nursing Facilities

19 **To the Editor:**

20 There is an increasing move towards screening carehome residents for cognitive issues. Many tools  
21 are available for cognitive assessment in older adults with little guidance on the optimal approach  
22 and consequent heterogeneity in approach.[1] The Alzheimer’s Society have produced a “toolkit”  
23 that recommends particular assessment tools for differing healthcare settings.[2] For carehomes,  
24 Hodkinson’s abbreviated mental test (AMT) [3] and/or General Practitioner assessment of cognition  
25 (GPCOG) are suggested as initial screens[4]. Where there is cognitive impairment the Montreal  
26 Cognitive Assessment (MoCA) [5] is suggested. All three tests may often be used, with AMT/GPCOG  
27 suggesting a cognitive impairment that is then characterised with MoCA.

28 There is a literature describing cognitive screening test properties such as accuracy and reliability.[6]  
29 Other important, but less well described, metrics are feasibility and acceptability. Understanding  
30 these properties is crucial for implementing a tool into practice. We sought to assess these  
31 properties for the cognitive assessments recommended for carehomes.

32

33 **Methods**

34 We performed cross-sectional assessment in all NHS continuing care (NHS-CC) units in Glasgow, UK.  
35 NHS-CC units offer professional nursing level care and frequent medical review to residents with  
36 complex physical and mental health needs.

37 Within each NHS-CC unit, the assessor approached senior staff to discuss suitability for cognitive  
38 testing. A standardised question was used “Do you feel this resident is suitable for any form of  
39 cognitive testing?” and final decision on whether testing would proceed was made by NHS-CC staff.  
40 A-priori we decided that patients in last days of life or where treatment was purely palliative would  
41 not be tested. Patients felt to be unsuitable for any form of testing (medically unstable, end of life  
42 care) were excluded, all other patients were approached for assessment.

43 We recorded if patients refused cognitive testing; were unable to attempt any of the tests or were  
44 unavailable on two occasions. Assessment was in a fixed order AMT, GPCOG and MoCA. Testing  
45 was performed in one session and if patient became distressed or struggled to complete testing then  
46 assessment was discontinued. We recorded test scores; time taken to complete tests and described  
47 numbers completing tests and resulting scores. The project was assessed as audit of practice and  
48 had approval from the local Caldicott guardian.

49 **Results**

50 We assessed patients across all six city NHS-CC units, n=222 patients, 107 (48%) had a formal  
51 dementia diagnosis.

52 In total 73 (33%) completed at least one test, median age:82 years (IQR: 76-88); n=50 female (40%);  
53 25 (34%) had a formal dementia diagnosis. All patients completed AMT, 23 (32%) completed all  
54 three tests.(Figure 1) Median assessment time:6 minutes (IQR: 4-15;range:2-34); for patients  
55 completing all three tests median assessment time:11minutes (IQR:15-24). At usual thresholds for  
56 “screen positive” n=3 (4%) screened as no cognitive impairment.(Figure 1)

57 Limiting to the 25 with formal dementia diagnosis (where MoCA is recommended as primary test), 6  
58 (24%) participants were able to complete MoCA testing, 12 (48%) completed GPCOG and all  
59 completed AMT.

60 **Discussion**

61 Our results highlight the challenges of even basic cognitive assessment in a carehome setting.

62 Routine assessment of *all* care-home residents using recommended tools may not be feasible and  
63 even a short test battery is associated with substantial non-completion and administration time.

64 The three recommended assessments have differing purposes and do not necessarily have to be  
65 administered in sequence. The added test burden of performing all three assessments in a single  
66 session may have biased results particularly for MoCA which was always performed last. Accepting  
67 this caveat, our data would suggest that AMT is a reasonable first step screening assessment. The  
68 low completion rate and high prevalence of cognitive impairment at usual thresholds suggests that  
69 MoCA may not be suited to carehome settings.

70 Our measures of test suitability, acceptance and completion suggest that issues with feasibility of a  
71 universal cognitive screening approach. We did not operationalize suitability for assessment but  
72 rather left this to the discretion of the senior unit staff. We feel this approach mirrors the real world  
73 setting. Although NHS-CC is a UK specific resource, the casemix will be similar to higher level  
74 “nursing home” / longterm care facilities and we feel our findings have external validity.

75

76 **Conclusion**

77 Time required and limited completion rates suggest that cognitive screening should use the shortest  
78 validated tool. With the very high prevalence of cognitive impairment in NHS-CC patients (at usual  
79 test thresholds) it could be argued whether “screening” for cognitive impairment per se is  
80 worthwhile. Targeted assessment for common incident problems that may require intervention  
81 such as delirium may be a more useful approach to cognitive assessment in carehome settings.

82 **Acknowledgments:** We wish to thank patients and staff of all the Glasgow continuing care units.

83

84 **Conflicts of interest:** None of the authors have conflicts of interest relevant to this work.

| Elements of Financial/Personal Conflicts | *Author 1 JS |    | Author 2 MMCE |    | Author 3 TQ |    |
|--|--------------|----|---------------|----|-------------|----|
|  | Yes          | No | Yes           | No | Yes         | No |
| Employment or Affiliation                |              | no |               | no |             | no |
|  |              |    |               |    |             |    |
| Grants/Funds                             |              | no |               | no |             | no |
|  |              |    |               |    |             |    |
| Honoraria                                |              | no |               | no |             | no |
|  |              |    |               |    |             |    |
| Speaker Forum                            |              | no |               | no |             | no |
|  |              |    |               |    |             |    |
| Consultant                               |              | no |               | no |             | no |
|  |              |    |               |    |             |    |
| Stocks                                   |              | no |               | no |             | no |
|  |              |    |               |    |             |    |
| Royalties                                |              | no |               | no |             | no |
|  |              |    |               |    |             |    |
| Expert Testimony                         |              | no |               | no |             | no |
|  |              |    |               |    |             |    |
| Board Member                             |              | no |               | no |             | no |
|  |              |    |               |    |             |    |
| Patents                                  |              | no |               | no |             | no |
|  |              |    |               |    |             |    |
| Personal Relationship                    |              | no |               | no |             | no |
|  |              |    |               |    |             |    |

85 \*Authors can be listed by abbreviations of their names.

86

87 **Author contributions:** Singh: data collection, analysis of data; McElroy: interpretation of data and  
88 preparation of manuscript; Quinn: study concept and design, interpretation of data, analysis of data  
89 and preparation of manuscript

90

91 **Sponsor's Role:** The sponsor had no role in the design, methods, subject recruitment, data  
92 collections, analysis, or preparation of this manuscript. Dr Terry Quinn is supported by a joint Chief  
93 Scientist Office / Stroke Association Senior Clinical Lecturer.


94

95 **References**

- 96 1. Shenkin SD, Russ TC, Ryan TM, Maclullich AMJ. Screening for dementia and other causes of  
97 cognitive impairment in general hospital in-patients. *Age Ageing*.2014;43:166-168.
- 98 2. Alzheimer’s Society. Assessing cognition in older people a practical toolkit for health professionals.  
99 [www.alzheimers.org.uk/cognitiveassessment](http://www.alzheimers.org.uk/cognitiveassessment).(accessed Sept 2014)
- 100 3. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the  
101 elderly. *Age Ageing*.1972; 1:233-8.
- 102 4. 1.Brody H, Pond D, Kemp NM, et al. The GPCOG: a new screening test for dementia designed for  
103 general practice. *J Am Geriatr Soc*.2002;50:530-4.
- 104 5. Nasreddine ZS, Phillips NA, Bedirian V. The Montreal Cognitive Assessment, MoCA:a brief  
105 screening tool for mild cognitive impairment. *J Am Geriatr Soc*.2005;53:695-9.
- 106 6. Quinn TJ, McShane R, Fearon P, Young C, Noel-Storr A, Stott DJ.IQCODE for the diagnosis of  
107 Alzheimer’s disease dementia and other dementias within a community setting. *Cochrane Database*  
108 *Systematic Reviews*.2013.CD010079.pub2



**Figure 1:** Flow diagram illustrating test completion and proportions completing and screening test positive for cognitive impairment



|                       | AMT<br>0-10 | GP-COG<br>0-9 | MoCA<br>0-30 | All tests |
|-----------------------|-------------|---------------|--------------|-----------|
| Completed test n      | 73          | 39            | 23           | 23        |
| Screen positive n (%) | 70 (96%)    | 27 (69%)      | 20 (87%)     | 20 (87%)  |
| Median score (IQR)    | 6 (3-8)     | 4 (2-6)       | 13 (10-22)   |           |